ArticleArthroplasty today2026
Does Timing Matter? Postoperative Risk and the Optimal Timing for Total Joint Arthroplasty Following COVID-19 Infection.
Article in Arthroplasty today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal timing of elective arthroplasty following COVID-19 infection remains unclear. While early postoperative risk is recognized, arthroplasty-specific data stratified by recovery interval are limited. We hypothesized that patients undergoing arthroplasty >12 weeks after COVID-19 would experience decreased complication risk. Methods: A retrospective cohort study evaluated outcomes following primary total hip arthroplasty and total knee arthroplasty (THA/TKA). Patients with documented preoperative COVID-19 infection were stratified by timing relative to surgery (<4 weeks, 4-12 weeks, >12 weeks) and compared to controls without prior infection. Primary outcomes included 1-year prosthetic joint infection, sepsis, revision surgery, deep vein thrombosis, and pulmonary embolism (PE). Results: A total of 37,272 THA and 57,158 TKA patients were included. Surgery within 4 weeks of infection was associated with increased risks of sepsis (THA relative risk [RR]: 2.36; TKA RR: 2.27) and PE (THA RR: 1.74; TKA RR: 2.39). In THA, deep vein thrombosis risk remained elevated at 4-12 weeks (RR: 1.49), and modest increases in sepsis and PE persisted beyond 12 weeks. In contrast, TKA demonstrated no increased systemic risk beyond 4 weeks. Prosthetic joint infection and revision rates were lower in patients undergoing surgery more than 12 weeks after infection. Conclusions: Elective THA and TKA performed within 4 weeks of COVID-19 infection are associated with increased systemic postoperative complications. While risk decreases with increasing time from infection, complications may persist beyond 12 weeks following THA. These findings support a timing-based approach to elective arthroplasty after COVID-19 infection. Level of Evidence: Level III.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.